AGBL3 and rheumatoid arthritis: After feature selection, the models achieved accuracies of 89.7%, 78.1%, and 96.8% on the test data when discriminating between Early RA vs At-Risk, Early RA vs anti-CCP3(−) Controls and At-Risk vs anti-CCP3(−) Controls, respectively.